Released lipids regulate Transient Receptor Potential Channel (TRP)-dependent oral cancer pain
© Ruparel et al. 2015
Received: 7 January 2015
Accepted: 25 March 2015
Published: 26 May 2015
Pain in the head neck area is an early symptom in oral cancer, supporting the hypothesis that cancer cells control the activities of surrounding nociceptors at the site of the tumor. Several reports implicate TRPV1 and TRPA1 in cancer pain, although there is a large gap in knowledge since the mechanisms for tumor-induced activation of these TRP receptors are unknown. Interestingly, TRP-active lipids such as linoleic acid, arachidonic acid, hydroxyoctadecadienoic acid and hydroxyeicosatetraenoic acid are significantly elevated in the saliva of oral cancer patients compared to normal patients, supporting a possible linkage between these lipids and oral cancer pain. We therefore hypothesize that oral squamous cell carcinomas release certain lipids that activate TRPV1 and/or TRPA1 on sensory neurons, contributing to the development of oral cancer pain.
Lipid extracts were made from conditioned media of three human oral squamous cell carcinoma (OSCC) cell lines as well as one normal human oral keratinocytes cell line. These were then injected intraplantarly into rat hindpaws to measure spontaneous nocifensive behavior, as well as thermal and mechanical allodynia. For interventional experiments, the animals were pretreated with AMG517 (TRPV1 antagonist) or HC030031 (TRPA1 antagonist) prior to extract injection.
These studies demonstrate that lipids released from the three OSCC cell lines, but not the normal cell line, were capable of producing significant spontaneous nocifensive behaviors, as well as thermal and mechanical allodynia. Notably each of the cell lines produced a different magnitude of response for each of three behavioral assays. Importantly, pre-treatment with a TRPVI antagonist blocked lipid-mediated nocifensive and thermal hypersensitivity, but not mechanical hypersensitivity. In addition, pre-treatment with a TRPA1 antagonist only reversed thermal hypersensitivity without affecting lipid-induced nocifensive behavior or mechanical allodynia.
These data reveal a novel mechanism for cancer pain and provide strong direction for future studies evaluating the cellular mechanism regulating the TRP-active lipids by OSCC tumors.
Pain due to cancer is notoriously difficult to treat, adds substantially to the emotional burden of having cancer, and is more frequently observed with certain cancer types such as with head and neck carcinomas (HNC). Indeed, 70–85 % of HNC patients report pain as their major symptom [1–4]. Patients typically report spontaneous pain as well as movement-related pain (i.e., mechanical allodynia) at the primary site of tumor development such as the tongue, floor of the mouth, larynx, oropharynx, hypopharynx and salivary glands [5, 6]. Many patients subsequently require opiates and tolerance rapidly develops for many HNC pain patients .
Despite the occurrence of pain in cancer, there is incomplete understanding of the mechanisms by which oral tumors evoke pain. Because pain is often the first symptom of oral cancer, occurring even when the tumor is still quite small in size, it is likely that oral cancer cells control the activities of surrounding nociceptors at the site of the tumor. A major class of trigeminal nociceptors express transient receptor potential (TRP) ion channels [8–10], including TRP vanilloid 1 (TRPV1), which has been implicated in oral cancer pain [7, 11]. However, the mechanism by which TRPV1 is activated during oral cancer is unknown.
Many polyunsaturated fatty acids (PUFA) are known to activate or sensitize TRPV1 [12–19]. However, no prior studies have evaluated the role of these lipids in mediating cancer pain. Interestingly, clinical studies have demonstrated that several TRP-active PUFAs such as linoleic acid, arachidonic acid, hydroxyoctadecadienoic acid (HODE) and hydroxyeicosatetraenoic acid (HETE) are significantly elevated in the saliva of oral cancer patients compared to normal patients, supporting a possible linkage between these lipids and oral cancer pain . In addition, TRPA1 is co-expressed with TRPV1 , is also activated by oxidized lipids [12, 22–24], modulates the activity of TRPV1 [25, 26] and may participate in cancer pain . Accordingly, we tested the novel hypothesis that oral squamous cell carcinomas release certain oxidized lipids that activate TRPV1 and TRPA1 on sensory neurons, contributing to the development of oral cancer pain.
Human oral squamous cell carcinoma (OSCC) cell lines; HSC2, HSC3 and HSC4 were purchased from Health Science Research Resources Bank, Japan. These cell lines were established from tumors obtained from male patients with the primary site of tumor being either the floor of the mouth or the tongue . The OSCC cell lines were cultivated and maintained in Dulbecco’s minimal essential medium (DMEM, Life Technologies, Carlsbad, CA) supplemented with glutamine, penicillin/streptomycin (pen-strep) and 10 % fetal bovine serum. The immortalized human normal oral keratinocyte (iNOK) cell line; OKF6-TERT2, was kindly provided by Dr. Cara Gonzales of UTHSCSA. This cell line was maintained in keratinocyte serum-free media (Life Technologies, Carlsbad, CA) supplemented with 25 ug/ml bovine pituitary extract (BPE), 0.2 ng/ml epidermal growth factor (EGF) and 0.4 uM calcium chloride.
All protocols were approved by the Institutional Animal Care and Use Committee of the University of Texas Health Science Center at San Antonio. Male Sprague–Dawley rats (Charles River Laboratories, Inc., Wilmington, MA, USA) were used for all experiments. Animals were housed for at least 7 days prior to the experiments.
The TRPV1 antagonist, AMG517 was purchased from Selleckchem (Houston, Texas, USA) and the TRPA1 antagonist, HC030031 was purchased from Tocris (Ellsville, Missouri, USA). Both drugs were diluted in 10 % DMSO/80 % mineral oil for peripheral injections and for systemic injections, AMG517 was diluted in 10 % DMSO/4 % Tween/PBS and HC030031 was diluted in 100 % DMSO.
Preparation of lipid extracts
Cells (3 × 105) were seeded per well of a 6-well plate. Twenty-four hours later, media was changed to 2 ml of basal minimal essential medium (MEM) without pH indicator, without FBS and supplemented with glutamine and pen-strep for OSCC cells and basal keratinocyte-serum free media with pen-strep but without BPE, EGF or calcium chloride. Following 24 hours, conditioned media was harvested and cells were trypsinized and counted using the TC20 automated cell counter (Bio-Rad). Conditioned media was subjected to lipid extraction using the Folch’s Method . Briefly, 10 ml of chloroform: methanol (2:1) was added to 2 ml of conditioned media and vortexed for 10 sec and incubated on ice for 30 min. The solution was then vortexed again for 10 sec, washed with saline and centrifuged at 8000 RPM for 10 min. The lower chloroform layer was collected and dried under nitrogen gas and stored at −80 °C until further use. Light exposure was minimized during lipid extraction. Immediately prior to experiments, the dried extracts were re-suspended in phosphate buffered saline.
All observers were blinded to treatment allocation. Three behavioral assays were used in the study to measure spontaneous nocifensive as well as evoked nociception in response to noxious stimuli. Spontaneous nocifensive behavior was carried out as described , whereas thermal allodynia was measured using the radiant heat test  and mechanical allodynia was measured using the dynamic aesthesiometer as described previously . The effect of OSCC-released lipids on nociception was studied by injecting 50 ul of re-suspended lipid extract into the plantar surface of the rat hindpaw. Nocifensive behavior (defined as spontaneous flinching, flexion movements or licking of the treated hindpaw) was recorded every 2 min up to a total of 10 min. Thermal and mechanical thresholds were measured from 10 to 150 min after injection.
To determine the role of TRPV1 and TRPA1 in mediating extract-induced nociceptive behaviors, animals were pretreated with vehicle, AMG517 or HC030031 45 min prior to extract injection. A systemic dose of 100 mg/kg of either drug, subcutaneously underneath the neck, was given for spontaneous nocifensive assays, whereas 100 ug of either drug was injected intraplantarly in the hindpaw for thermal and mechanical threshold measurements. The doses for each drug were selected based on previously published literature [33–36]. Nocifensive behavior was measured for 10 min whereas thermal and mechanical thresholds were measured at the peak time of allodynia; which was 10 min post injection of the lipid extract. Paw withdrawal thresholds for ipsilateral as well as contralateral hindpaws were measured.
Data are presented as mean ± SEM. Statistical analyses were performed using one-way or two-way ANOVA with Sidak’s post-hoc test. A statistically significant difference was defined as P < 0.05. Error bars are standard error of the mean (S.E.M).
OSCC-released lipids induce nocifensive behavior in rats in a TRPV1-dependent manner
To determine whether OSCC-released lipids induce nocifensive behavior via activation of TRPV1 and/or TRPA1, rats were pretreated with a systemic dose of specific TRPV1 (AMG517, 3 mg/kg) or TRPA1 antagonist (HC030031, 30 mg/kg) prior to injection of HSC2 lipid extract. As seen in Fig. 1c, AMG517 pretreatment virtually abolished lipid-induced nocifensive behavior, whereas HC030031 pretreatment had no effect.
OSCC-released lipids induce thermal and mechanical allodynia in rats
OSCC-released lipids mediate thermal but not mechanical allodynia via TRPV1 and TRPA1 channels
Two distinct features of pain reports from oral cancer patients are that: 1) the pain is specific to malignant lesions and is not observed in pre-cancerous or non-cancerous lesions [37, 38]; and 2) significant pain occurs even when the tumor is still quite small in size. These aspects of oral cancer pain are consistent with the hypothesis that oral squamous cell carcinoma cells directly modulate activities of peripheral nociceptors. The TRP channels are one class of receptors expressed on the membranes of trigeminal primary afferents terminating in the oral cavity [8–10, 21]. Recent reports have shown that TRPV1 may play a role in oral cancer pain. For example, TRPV1 expression in trigeminal ganglia neurons increases after tumor growth in the oral cavity of rats  and ablation of TRPV1+ neurons reduced OSCC-induced thermal hyperalgesia . The current study therefore explored the mechanism by which TRPV1 activities are regulated in peripheral sensory neurons during oral cancer pain. Polyunsaturated fatty acids (PUFAs) are a possible class of factors since human saliva from oral cancer patients has been reported to have elevated levels of certain TRP-active PUFAs (e.g., linoleic acid, arachidonic acid, HODE, and HETE), compared to normal control patients , and many of these PUFAs activate TRPV1 [12–19] or TRPA1 [12, 22–24]. We therefore evaluated the role of OSCC-secreted lipids in mediating TRP-dependent oral cancer pain using a combined approach of in vitro OSCC cell cultures to generate lipid extracts followed by in vivo measurement of nociception in rats. This approach focuses on direct effects of tumor cells on peripheral nociceptors without involvement of carcinogenesis, activation of the immune system or alterations in the extracellular matrix.
It has been reported that most HNC patients reporting pain have cancerous lesion in the mouth region . We therefore, used three human OSCC cell lines for our study, namely, HSC2, HSC3 and HSC4, that were derived from tumors obtained from patients with the primary site of tumor being either the floor of the mouth or the tongue .
Our data demonstrate that lipids extracted from conditioned media of the OSCC cell lines evoked nocifensive behavior as well as significant thermal and mechanical allodynia (Figs. 1a, 2b, c, and d and 3a, b, and c). Interestingly, the responses observed for each of the three behavioral modalities, were different between the three cell lines. This finding of OSCC heterogeneity may contribute to the observed high variation in pain intensity reported by HNC patients. Importantly, these nociceptive substances appear to be derived from cancerous cells since there were no nociceptive responses observed with lipid extracts from normal oral keratinocyte cells. Moreover, the collection of conditioned media precluded any contribution from other cell types (e.g., immune cells, endothelium, etc.) that might co-exist in a tumor mass grown in vivo. Thus, OSCC release bioactive substances that modulate nociceptor activity. Prior studies have reported that OSCC cells may release certain protein or peptides such as endothelin-1 , nerve growth factor (NGF)  or trypsin , to activate peripheral afferents. However, these and other hydrophilic compounds are excluded by the Folch’s extraction method  and thus the present findings demonstrate, for the first time, that lipids released from OSCC cells may contribute to oral cancer pain.
The data also demonstrate a key role for TRPV1 in mediating nociception induced by OSCC-derived lipid extracts. Pre-treatment with a TRPV1 antagonist completely abolished lipid-mediated nocifensive responses and significantly inhibited thermal allodynia. Further, the data indicate that the site of action of the TRPV1 antagonist was peripheral since injection of the drug in the contralateral paw did not affect lipid-induced thermal allodynia. However, TRPV1 is not the only receptor system contributing to lipid-induced nociception. This conclusion is based on two findings. First, a TRPA1 antagonist had significant attenuation of thermal allodynia. Second, neither the TRPV1 nor the TRPA1 antagonist altered mechanical allodynia due to OSCC-derived lipids. Thus, OSCC-released lipids evoke nociception via multiple mechanisms of action. Identifying the specific lipids from OSCC cells can provide further insights into mechanisms by which these lipids induce oral cancer pain as well as, ways to target their release for development of novel analgesics to treat oral cancer pain.
The study was supported by UTHSCSA seed funding (to SR) and funding obtained from William and Ella Owen's Medical Research Foundation (to SR).
- Chaplin JM, Morton RP. A prospective, longitudinal study of pain in head and neck cancer patients. Head Neck. 1999;21:531–7.PubMedView ArticleGoogle Scholar
- Epstein JB, Stewart KH. Radiation therapy and pain in patients with head and neck cancer. Eur J Cancer B Oral Oncol. 1993;29B:191–9.PubMedView ArticleGoogle Scholar
- Keefe FJ, Manuel G, Brantley A, Crisson J. Pain in the head and neck cancer patient: changes over treatment. Head Neck Surg. 1986;8:169–76.PubMedView ArticleGoogle Scholar
- Saxena A, Gnanasekaran N, Andley M. An epidemiological study of prevalence of pain in head & neck cancers. Indian J Med Res. 1995;102:28–33.PubMedGoogle Scholar
- Cuffari L, de Siqueira JT T, Nemr K, Rapaport A. Pain complaint as the first symptom of oral cancer: a descriptive study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:56–61.PubMedView ArticleGoogle Scholar
- Lam DK, Schmidt BL. Orofacial pain onset predicts transition to head and neck cancer. Pain. 2011;152:1206–9.PubMed CentralPubMedView ArticleGoogle Scholar
- Nagamine K, Ozaki N, Shinoda M, Asai H, Nishiguchi H, Mitsudo K, et al. Mechanical allodynia and thermal hyperalgesia induced by experimental squamous cell carcinoma of the lower gingiva in rats. J Pain. 2006;7:659–70.PubMedView ArticleGoogle Scholar
- Elitt CM, Malin SA, Koerber HR, Davis BM, Albers KM. Overexpression of artemin in the tongue increases expression of TRPV1 and TRPA1 in trigeminal afferents and causes oral sensitivity to capsaicin and mustard oil. Brain Res. 2008;1230:80–90.PubMed CentralPubMedView ArticleGoogle Scholar
- Kanazawa T, Matsumoto S. Expression of transient receptor potential vanilloid 1 and anoctamin 1 in rat trigeminal ganglion neurons innervating the tongue. Brain Res Bull. 2014;106:17–20.PubMedView ArticleGoogle Scholar
- Kido MA, Muroya H, Yamaza T, Terada Y, Tanaka T. Vanilloid receptor expression in the rat tongue and palate. J Dent Res. 2003;82:393–7.PubMedView ArticleGoogle Scholar
- Ye Y, Bae SS, Viet CT, Troob S, Bernabe D, Schmidt BL. IB4(+) and TRPV1(+) sensory neurons mediate pain but not proliferation in a mouse model of squamous cell carcinoma. Behav Brain Funct. 2014;10:5.PubMed CentralPubMedView ArticleGoogle Scholar
- Gregus AM, Doolen S, Dumlao DS, Buczynski MW, Takasusuki T, Fitzsimmons BL, et al. Spinal 12-lipoxygenase-derived hepoxilin A3 contributes to inflammatory hyperalgesia via activation of TRPV1 and TRPA1 receptors. Proc Natl Acad Sci. 2012;109:6721–6.PubMed CentralPubMedView ArticleGoogle Scholar
- Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A. 2000;97:6155–60.PubMed CentralPubMedView ArticleGoogle Scholar
- Moriyama T, Higashi T, Togashi K, Iida T, Segi E, Sugimoto Y, et al. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain. 2005;1:3.PubMed CentralPubMedView ArticleGoogle Scholar
- Patwardhan AM, Scotland PE, Akopian AN, Hargreaves KM. Activation of TRPV1 in the spinal cord by oxidized linoleic acid metabolites contributes to inflammatory hyperalgesia. Proc Natl Acad Sci U S A. 2009;106:18820–4.PubMed CentralPubMedView ArticleGoogle Scholar
- Ruparel S, Green D, Chen P, Hargreaves KM. The cytochrome P450 inhibitor, ketoconazole, inhibits oxidized linoleic acid metabolite-mediated peripheral inflammatory pain. Mol Pain. 2012;8:73.PubMed CentralPubMedView ArticleGoogle Scholar
- Suh YG, Oh U. Activation and activators of TRPV1 and their pharmaceutical implication. Curr Pharm Des. 2005;11:2687–98.PubMedView ArticleGoogle Scholar
- Wen H, Ostman J, Bubb KJ, Panayiotou C, Priestley JV, Baker MD, et al. 20-Hydroxyeicosatetraenoic acid (20-HETE) is a novel activator of transient receptor potential vanilloid 1 (TRPV1) channel. J Biol Chem. 2012;287:13868–76.PubMed CentralPubMedView ArticleGoogle Scholar
- Patwardhan AM, Akopian AN, Ruparel NB, Diogenes A, Weintraub ST, Uhlson C, et al. Heat generates oxidized linoleic acid metabolites that activate TRPV1 and produce pain in rodents. J Clin Invest. 2010;120:1617–26.PubMed CentralPubMedView ArticleGoogle Scholar
- Metzger K, Angres G, Maier H, Lehmann WD. Lipoxygenase products in human saliva: patients with oral cancer compared to controls. Free Radic Biol Med. 1995;18:185–94.PubMedView ArticleGoogle Scholar
- Diogenes A, Akopian AN, Hargreaves KM. NGF up-regulates TRPA1: implications for orofacial pain. J Dent Res. 2007;86:550–5.PubMedView ArticleGoogle Scholar
- Brenneis C, Sisignano M, Coste O, Altenrath K, Fischer MJ, Angioni C, et al. Soluble epoxide hydrolase limits mechanical hyperalgesia during inflammation. Mol Pain. 2011;7:78.PubMed CentralPubMedView ArticleGoogle Scholar
- Sisignano M, Park CK, Angioni C, Zhang DD, von Hehn C, Cobos EJ, et al. 5,6-EET is released upon neuronal activity and induces mechanical pain hypersensitivity via TRPA1 on central afferent terminals. J Neurosci. 2012;32:6364–72.PubMed CentralPubMedView ArticleGoogle Scholar
- Motter AL, Ahern GP. TRPA1 is a polyunsaturated fatty acid sensor in mammals. PLoS One. 2012;7:e38439.PubMed CentralPubMedView ArticleGoogle Scholar
- Jeske NA, Patwardhan AM, Gamper N, Price TJ, Akopian AN, Hargreaves KM. Cannabinoid WIN 55,212-2 regulates TRPV1 phosphorylation in sensory neurons. J Biol Chem. 2006;281:32879–90.PubMed CentralPubMedView ArticleGoogle Scholar
- Staruschenko A, Jeske NA, Akopian AN. Contribution of TRPV1-TRPA1 interaction to the single channel properties of the TRPA1 channel. J Biol Chem. 2010;285:15167–77.PubMed CentralPubMedView ArticleGoogle Scholar
- Trevisan G, Materazzi S, Fusi C, Altomare A, Aldini G, Lodovici M, et al. Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. Cancer Res. 2013;73:3120–31.PubMedView ArticleGoogle Scholar
- Michi Y, Morita I, Amagasa T, Murota S. Human oral squamous cell carcinoma cell lines promote angiogenesis via expression of vascular endothelial growth factor and upregulation of KDR/flk-1 expression in endothelial cells. Oral Oncol. 2000;36:81–8.PubMedView ArticleGoogle Scholar
- Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226:497–509.PubMedGoogle Scholar
- Ruparel S, Hargreaves KM, Eskander M, Rowan S, de Almeida JF, Roman L, et al. Oxidized linoleic acid metabolite-cytochrome P450 system (OLAM-CYP) is active in biopsy samples from patients with inflammatory dental pain. Pain. 2013;154:2363–71.PubMedView ArticleGoogle Scholar
- Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32:77–88.PubMedView ArticleGoogle Scholar
- Gibbs JL, Flores CM, Hargreaves KM. Attenuation of capsaicin-evoked mechanical allodynia by peripheral neuropeptide Y Y1 receptors. Pain. 2006;124:167–74.PubMedView ArticleGoogle Scholar
- da Costa DS, Meotti FC, Andrade EL, Leal PC, Motta EM, Calixto JB. The involvement of the transient receptor potential A1 (TRPA1) in the maintenance of mechanical and cold hyperalgesia in persistent inflammation. Pain. 2010;148:431–7.PubMedView ArticleGoogle Scholar
- Eid SR, Crown ED, Moore EL, Liang HA, Choong KC, Dima S, et al. HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity. Mol Pain. 2008;4:48.PubMed CentralPubMedView ArticleGoogle Scholar
- Gavva NR, Bannon AW, Hovland Jr DN, Lehto SG, Klionsky L, Surapaneni S, et al. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J Pharmacol Exp Ther. 2007;323:128–37.PubMedView ArticleGoogle Scholar
- Green DP, Ruparel S, Roman L, Henry MA, Hargreaves KM. Role of endogenous TRPV1 agonists in a postburn pain model of partial-thickness injury. Pain. 2013;154:2512–20.PubMedView ArticleGoogle Scholar
- Mashberg A, Samit A. Early diagnosis of asymptomatic oral and oropharyngeal squamous cancers. CA Cancer J Clin. 1995;45:328–51.PubMedView ArticleGoogle Scholar
- Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002;52:195–215.PubMedView ArticleGoogle Scholar
- Grond S, Zech D, Diefenbach C, Radbruch L, Lehmann KA. Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain. 1996;64:107–14.PubMedView ArticleGoogle Scholar
- Pickering V, Jay Gupta R, Quang P, Jordan RC, Schmidt BL. Effect of peripheral endothelin-1 concentration on carcinoma-induced pain in mice. Eur J Pain. 2008;12:293–300.PubMed CentralPubMedView ArticleGoogle Scholar
- Ye Y, Dang D, Zhang J, Viet CT, Lam DK, Dolan JC, et al. Nerve growth factor links oral cancer progression, pain, and cachexia. Mol Cancer Ther. 2011;10:1667–76.PubMed CentralPubMedView ArticleGoogle Scholar
- Lam DK, Dang D, Zhang J, Dolan JC, Schmidt BL. Novel animal models of acute and chronic cancer pain: a pivotal role for PAR2. J Neurosci. 2012;32:14178–83.PubMed CentralPubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.